La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GE HealthCare Technologies Salute del bilancio

Salute finanziaria criteri di controllo 3/6

GE HealthCare Technologies ha un patrimonio netto totale di $8.0B e un debito totale di $9.2B, che porta il suo rapporto debito/patrimonio netto a 115.6%. Le sue attività totali e le sue passività totali sono rispettivamente $31.9B e $23.9B. L'EBIT di GE HealthCare Technologies è $2.9B rendendo il suo rapporto di copertura degli interessi 5.6. Ha liquidità e investimenti a breve termine pari a $2.0B.

Informazioni chiave

115.6%

Rapporto debito/patrimonio netto

US$9.24b

Debito

Indice di copertura degli interessi	5.6x
Contanti	US$2.00b
Patrimonio netto	US$7.99b
Totale passività	US$23.86b
Totale attività	US$31.85b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $8.8B ) di L0T superano le sue passività a breve termine ( $8.3B ).

Passività a lungo termine: Le attività a breve termine di L0T ( $8.8B ) non coprono le sue passività a lungo termine ( $15.5B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 90.6% ) di L0T è considerato alto.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di L0T si sia ridotto negli ultimi 5 anni.

Copertura del debito: Il debito di L0T è ben coperto dal flusso di cassa operativo ( 21.6% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di L0T sono ben coperti dall'EBIT ( 5.6 x copertura).

GE HealthCare Technologies Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

GE HealthCare Announces the Publication of the MASTER Trial Results in the Peer-Reviewed Journal Anesthesia and Analgesia

Insider recently sold €1.4m worth of stock

Second quarter 2024 earnings released: EPS: US$0.94 (vs US$0.92 in 2Q 2023)

GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q2, 2024 Results on Jul 31, 2024

First quarter dividend of US$0.03 announced

GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024

GE Healthcare Names Adam Holton as Chief People Officer

GE HealthCare Unveils SIGNA MAGNUS, an FDA 510(K) Pending Head-Only Magnetic Resonance (MR) Scanner Designed to Explore Advance Advancements in Neuro Science

GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress

First quarter 2024 earnings released: EPS: US$0.82 (vs US$0.41 in 1Q 2023)

GE HealthCare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2024

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women's Health Imaging

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q1, 2024 Results on Apr 30, 2024

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

GE Healthcare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

GE HealthCare Technologies Inc. to Feature Latest Technologies in Interventional Radiology Focused on Precision Care At Sir 2024

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

Now 23% overvalued after recent price rise

GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.06925 billion.

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

New minor risk - Profit margin trend

Full year 2023 earnings released

Now 29% overvalued after recent price rise

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Full Year of 2024

GE HealthCare Technologies Inc. Receives 510(K) Clearance from the United States Food and Drug Administration for Novii™+ Wireless Patch Solution

GE HealthCare Technologies Inc. Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation

Now 20% overvalued after recent price rise

GE HealthCare Technologies Inc. to Report Q4, 2023 Results on Feb 06, 2024

GE HealthCare Technologies Inc. (NasdaqGS:GEHC) entered into definitive agreement to acquire MIM Software Inc.

Upcoming dividend of US$0.03 per share at 0.2% yield

GE HealthCare Highlights Commitment to Delivering Better Patient Experiences and Outcomes Through Deep Learning at RSNA 2023

GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis

GE HealthCare Technologies Inc. Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

GE Healthcare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released

GE HealthCare Technologies Inc. Announces to Showcase Some of the Latest Innovations Designed to Help Clinicians in the Treatment of Cardiovascular Disease At the 2023 Transcatheter Cardiovascular Therapeutics Conference

GE HealthCare Technologies Inc. to Report Q3, 2023 Results on Oct 31, 2023

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

GE HealthCare Launches Enhanced Venue Family Ultrasound Systems Featuring AI-Driven Caption Guidance

GE HealthCare Technologies Inc. Announces Cash Dividend for Third Quarter of 2023, Payable on November 15, 2023

GE HealthCare Introduces Vscan Air SL, Wireless Handheld Ultrasound Device for Rapid Assessments of Cardiac and Vascular Patients

GE HealthCare Technologies Inc. Receives FDA Clearance for Portrait Mobile, Wireless Monitoring Solution Aiding Early Detection of Patient Deterioration

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.92 (vs US$1.04 in 2Q 2022)

Upcoming dividend of US$0.03 per share at 0.1% yield

GE HealthCare Technologies Inc. to Report Q2, 2023 Results on Jul 25, 2023

GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of Fiscal Year 2023, Payable on August 15, 2023

GE HealthCare Technologies Inc. Announces the First Patient Scanned in a Phase I Clinical Trial of a Fluorine-18 PET Radiopharmaceutical

GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.95 billion.

GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.95 billion.

GE HealthCare Releases Reimagining Better Health

GE HealthCare Introduces Sonic DL

GE HealthCare Technologies Inc. Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

GE HealthCare Technologies Inc. Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

GE HealthCare Introduces Innovations to Improve Radiation Therapy Efficiency and Precision Care at the European Society for Therapeutic Radiology and Oncology 2023 Congress

GE Healthcare Technologies Inc. Announces Chief Financial Officer Changes, Effective from June 1, 2023

First quarter 2023 earnings released

CEO of Imaging recently sold €414k worth of stock

GE HealthCare Technologies Inc. (NasdaqGS : GEHC) signed an agreement to acquire Caption Health, Inc.

Now 21% undervalued

Full year 2022 earnings released

No independent directors

GE Healthcare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2023

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane